ALK and non-small cell lung carcinoma: To allow Canadian patients with ALK-positive NSCLC progressing on second-generation ALK TKIs to have access to targeted therapy, a time-limited Canadian patient access program for lorlatinib was operated by Pfizer Canada ULC.